OCA
CRDF icon

Octagon Capital Advisors’s Cardiff Oncology CRDF Stock Holding History

Octagon Capital Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-982,753
Closed -$5.91M – 26
2021
Q4 		$5.91M Hold
982,753
– – 1.15% 19
2021
Q3 		$6.54M Hold
982,753
– – 1.61% 18
2021
Q2 		$6.54M Buy
982,753
+332,753
+51% +$2.82M 1.35% 21
2021
Q1 		$6.02M Hold
650,000
– – 2.27% 18
2020
Q4 		$11.7M Buy
+650,000
New +$11.4M 4.05% 11

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Octagon Capital Advisors's CRDF Position: Q1 2022 in Review

Octagon Capital Advisors sold out of Cardiff Oncology (CRDF) in Q1 2022, closing a stake of 982,753 shares — an estimated $5.91M sold.

Octagon Capital Advisors first reported a position in CRDF in Q4 2020 and held it in 5 quarters. The position peaked at $11.7M in Q4 2020. 91 funds tracked by Wall St. Rank hold CRDF as of Q1 2022.

  • Octagon Capital Advisors reported no remaining Cardiff Oncology position as of Q1 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 982,753 Cardiff Oncology shares in Q1 2022, an estimated $5.91M.
  • Octagon Capital Advisors first reported a position in Cardiff Oncology in Q4 2020 and held it in 5 quarters.
  • Octagon Capital Advisors's Cardiff Oncology position peaked at $11.7M in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2022.

Based on Octagon Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.